Real-world Clinical Outcomes in Patients with Limited Stage SCLC Who Received High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy versus Standard-dose radiotherapy.
OpenAlex 토픽 ·
Lung Cancer Research Studies
Advanced Radiotherapy Techniques
Brain Metastases and Treatment
[BACKGROUND] A phase 3 trial has shown that high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) is clinically effective for limited-stage small-cell lu
- p-value p=0.011
- p-value p=0.033
- 95% CI 11.8-30.4
- 추적기간 54.9 months
- 연구 설계 cohort study
APA
Jiayi Yu, Jingwei Zhang, et al. (2026). Real-world Clinical Outcomes in Patients with Limited Stage SCLC Who Received High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy versus Standard-dose radiotherapy.. Practical radiation oncology. https://doi.org/10.1016/j.prro.2026.04.007
MLA
Jiayi Yu, et al.. "Real-world Clinical Outcomes in Patients with Limited Stage SCLC Who Received High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy versus Standard-dose radiotherapy.." Practical radiation oncology, 2026.
PMID
42034286
Abstract
[BACKGROUND] A phase 3 trial has shown that high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) is clinically effective for limited-stage small-cell lung cancer (LS-SCLC) patients under 70. This retrospective study compares the real-world effectiveness of high-dose hyperfractionated simultaneous integrated boost radiotherapy with standard-dose radiotherapy.
[METHODS] This retrospective study was conducted at ****, including patients with histologically or cytologically confirmed LS-SCLC. All eligible patients received four courses of thoracic radiotherapy combined with concurrent chemotherapy (cisplatin or carboplatin and etoposide). Patients were categorized into three groups based on the radiotherapy dose: the 54 Gy group (54 Gy in 30 fractions, twice daily), the 45 Gy group (45 Gy in 30 fractions, twice daily), and the 60 Gy group (60-70 Gy in 30-35 fractions, once daily). The primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS).
[RESULTS] Between March 2010 and November 2024, a total of 353 patients were inclued in the study. The median follow-up was 54.9 months (range, 2.9 to 151.6). After applying inverse probability of treatment weighting (IPTW), the clinical features were well balanced between the groups. The median rwPFS was significantly better in the 54 Gy group (29.7 months [95% CI 15.9-NA]) compared to the 45 Gy group (15.0 months [95% CI 11.8-30.4]; hazard ratio 1.23 [95% CI 1.01-1.50]) and the 60 Gy group (13.5 months [95% CI 11.4-15.9]; HR 1.29 [95% CI 1.09-1.54]) both before (p=0.011) and after (p=0.033) IPTW. The median OS was also significantly longer in the 54 Gy group (63.9 months [95% CI 57.1-NA]) compared to the 45 Gy group (42.9 months [95% CI 32.3-70.8]; HR 1.76 [95% CI 1.19-2.61]) and the 60 Gy group (38.0 months [95% CI 30.8-51.9]; HR 1.60 [95% CI 1.05-2.44]) both before (p=0.015) and after (p=0.006) IPTW. Treatment-related toxicities were similar across the three groups.
[CONCLUSION] High-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy) was well tolerated and effective in this large, real-world cohort study of patients with LS-SCLC compared with standard-dose (45 Gy bid & 60-70 Gy qd) radiotherapy.
[METHODS] This retrospective study was conducted at ****, including patients with histologically or cytologically confirmed LS-SCLC. All eligible patients received four courses of thoracic radiotherapy combined with concurrent chemotherapy (cisplatin or carboplatin and etoposide). Patients were categorized into three groups based on the radiotherapy dose: the 54 Gy group (54 Gy in 30 fractions, twice daily), the 45 Gy group (45 Gy in 30 fractions, twice daily), and the 60 Gy group (60-70 Gy in 30-35 fractions, once daily). The primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS).
[RESULTS] Between March 2010 and November 2024, a total of 353 patients were inclued in the study. The median follow-up was 54.9 months (range, 2.9 to 151.6). After applying inverse probability of treatment weighting (IPTW), the clinical features were well balanced between the groups. The median rwPFS was significantly better in the 54 Gy group (29.7 months [95% CI 15.9-NA]) compared to the 45 Gy group (15.0 months [95% CI 11.8-30.4]; hazard ratio 1.23 [95% CI 1.01-1.50]) and the 60 Gy group (13.5 months [95% CI 11.4-15.9]; HR 1.29 [95% CI 1.09-1.54]) both before (p=0.011) and after (p=0.033) IPTW. The median OS was also significantly longer in the 54 Gy group (63.9 months [95% CI 57.1-NA]) compared to the 45 Gy group (42.9 months [95% CI 32.3-70.8]; HR 1.76 [95% CI 1.19-2.61]) and the 60 Gy group (38.0 months [95% CI 30.8-51.9]; HR 1.60 [95% CI 1.05-2.44]) both before (p=0.015) and after (p=0.006) IPTW. Treatment-related toxicities were similar across the three groups.
[CONCLUSION] High-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy) was well tolerated and effective in this large, real-world cohort study of patients with LS-SCLC compared with standard-dose (45 Gy bid & 60-70 Gy qd) radiotherapy.
같은 제1저자의 인용 많은 논문 (5)
- The highest region of muscle spindle abundance should be the optimal target of botulinum toxin A injection to block muscle spasms in rats.
- Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation.
- Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.
- KDM5D epigenetically represses FERD3L to inhibit tumor growth in male colorectal cancer.
- Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses.